CN110951703B - 一种间日疟原虫乳酸脱氢酶重组蛋白及其单克隆抗体的制备 - Google Patents
一种间日疟原虫乳酸脱氢酶重组蛋白及其单克隆抗体的制备 Download PDFInfo
- Publication number
- CN110951703B CN110951703B CN201911334841.5A CN201911334841A CN110951703B CN 110951703 B CN110951703 B CN 110951703B CN 201911334841 A CN201911334841 A CN 201911334841A CN 110951703 B CN110951703 B CN 110951703B
- Authority
- CN
- China
- Prior art keywords
- recombinant protein
- lactate dehydrogenase
- plasmodium vivax
- monoclonal antibody
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000003855 L-lactate dehydrogenase Human genes 0.000 title claims abstract description 51
- 108700023483 L-lactate dehydrogenases Proteins 0.000 title claims abstract description 51
- 241000223810 Plasmodium vivax Species 0.000 title claims abstract description 48
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims abstract description 47
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000000427 antigen Substances 0.000 claims abstract description 17
- 102000036639 antigens Human genes 0.000 claims abstract description 17
- 108091007433 antigens Proteins 0.000 claims abstract description 17
- 239000004005 microsphere Substances 0.000 claims abstract description 16
- 230000014509 gene expression Effects 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims abstract description 11
- 238000012216 screening Methods 0.000 claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 4
- 238000002474 experimental method Methods 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 8
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 241000588724 Escherichia coli Species 0.000 claims description 9
- 241000699670 Mus sp. Species 0.000 claims description 8
- 210000004408 hybridoma Anatomy 0.000 claims description 8
- 238000001976 enzyme digestion Methods 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 4
- 239000013600 plasmid vector Substances 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 210000004989 spleen cell Anatomy 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 150000002333 glycines Chemical class 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 201000004792 malaria Diseases 0.000 abstract description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract description 4
- 239000012634 fragment Substances 0.000 abstract description 4
- 230000003053 immunization Effects 0.000 abstract description 4
- 238000002649 immunization Methods 0.000 abstract description 3
- 238000013399 early diagnosis Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 230000007910 cell fusion Effects 0.000 abstract 1
- 210000001236 prokaryotic cell Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 238000005406 washing Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 239000012528 membrane Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 241000224016 Plasmodium Species 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QJWLLRZTJFPCHA-STECZYCISA-N Arg-Tyr-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O QJWLLRZTJFPCHA-STECZYCISA-N 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- OLPPXYMMIARYAL-QMMMGPOBSA-N Gly-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)CN OLPPXYMMIARYAL-QMMMGPOBSA-N 0.000 description 3
- BHPQOIPBLYJNAW-NGZCFLSTSA-N Gly-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN BHPQOIPBLYJNAW-NGZCFLSTSA-N 0.000 description 3
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 3
- LAPSXOAUPNOINL-YUMQZZPRSA-N Leu-Gly-Asp Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O LAPSXOAUPNOINL-YUMQZZPRSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- IUVYJBMTHARMIP-PCBIJLKTSA-N Phe-Asp-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O IUVYJBMTHARMIP-PCBIJLKTSA-N 0.000 description 3
- 206010035503 Plasmodium vivax infection Diseases 0.000 description 3
- 201000009976 Plasmodium vivax malaria Diseases 0.000 description 3
- MRYUJHGPZQNOAD-IHRRRGAJSA-N Pro-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1 MRYUJHGPZQNOAD-IHRRRGAJSA-N 0.000 description 3
- AKHDFZHUPGVFEJ-YEPSODPASA-N Thr-Val-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AKHDFZHUPGVFEJ-YEPSODPASA-N 0.000 description 3
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 3
- ODUHAIXFXFACDY-SRVKXCTJSA-N Val-Val-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)C(C)C ODUHAIXFXFACDY-SRVKXCTJSA-N 0.000 description 3
- 208000005469 Vivax Malaria Diseases 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 3
- 238000003317 immunochromatography Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 108010068488 methionylphenylalanine Proteins 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 description 2
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 239000012880 LB liquid culture medium Substances 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000002476 Falciparum Malaria Diseases 0.000 description 1
- XMPXVJIDADUOQB-RCOVLWMOSA-N Gly-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)CNC(=O)C[NH3+] XMPXVJIDADUOQB-RCOVLWMOSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- QHUREMVLLMNUAX-OSUNSFLBSA-N Ile-Thr-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)O)N QHUREMVLLMNUAX-OSUNSFLBSA-N 0.000 description 1
- GGAPIOORBXHMNY-ULQDDVLXSA-N Lys-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)O GGAPIOORBXHMNY-ULQDDVLXSA-N 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 241000242677 Schistosoma japonicum Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 1
- MUUGCDGGIVCSDT-UHFFFAOYSA-N [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O MUUGCDGGIVCSDT-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 238000003453 ammonium sulfate precipitation method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000028744 lysogeny Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01027—L-Lactate dehydrogenase (1.1.1.27)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01028—D-Lactate dehydrogenase (1.1.1.28)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911334841.5A CN110951703B (zh) | 2019-12-23 | 2019-12-23 | 一种间日疟原虫乳酸脱氢酶重组蛋白及其单克隆抗体的制备 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911334841.5A CN110951703B (zh) | 2019-12-23 | 2019-12-23 | 一种间日疟原虫乳酸脱氢酶重组蛋白及其单克隆抗体的制备 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110951703A CN110951703A (zh) | 2020-04-03 |
CN110951703B true CN110951703B (zh) | 2023-04-07 |
Family
ID=69983572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911334841.5A Active CN110951703B (zh) | 2019-12-23 | 2019-12-23 | 一种间日疟原虫乳酸脱氢酶重组蛋白及其单克隆抗体的制备 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110951703B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115785275B (zh) * | 2021-09-10 | 2023-09-22 | 东莞市朋志生物科技有限公司 | 一种抗疟原虫的抗体及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101659975A (zh) * | 2009-05-18 | 2010-03-03 | 杭州贤至生物科技有限公司 | 一种恶性疟原虫hrpii蛋白单克隆抗体的制备方法 |
CN101921337A (zh) * | 2010-07-21 | 2010-12-22 | 上海市疾病预防控制中心 | 间日疟原虫乳酸脱氢酶抗体、相关制备方法、杂交瘤细胞株和应用 |
CN102816763A (zh) * | 2011-06-07 | 2012-12-12 | 浦项工科大学校产学协力团 | 特异性结合于疟原虫乳酸脱氢酶pLDH的DNA适体 |
CN104450625A (zh) * | 2014-11-17 | 2015-03-25 | 深圳市菲鹏生物股份有限公司 | 可分泌抗疟原虫乳酸脱氢酶单克隆抗体的杂交瘤细胞、单克隆抗体及应用 |
-
2019
- 2019-12-23 CN CN201911334841.5A patent/CN110951703B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101659975A (zh) * | 2009-05-18 | 2010-03-03 | 杭州贤至生物科技有限公司 | 一种恶性疟原虫hrpii蛋白单克隆抗体的制备方法 |
CN101921337A (zh) * | 2010-07-21 | 2010-12-22 | 上海市疾病预防控制中心 | 间日疟原虫乳酸脱氢酶抗体、相关制备方法、杂交瘤细胞株和应用 |
CN102816763A (zh) * | 2011-06-07 | 2012-12-12 | 浦项工科大学校产学协力团 | 特异性结合于疟原虫乳酸脱氢酶pLDH的DNA适体 |
CN104450625A (zh) * | 2014-11-17 | 2015-03-25 | 深圳市菲鹏生物股份有限公司 | 可分泌抗疟原虫乳酸脱氢酶单克隆抗体的杂交瘤细胞、单克隆抗体及应用 |
Non-Patent Citations (3)
Title |
---|
间日疟原虫乳酸脱氢酶单克隆抗体的制备及其鉴定;孙莉等;《广东医学》;20100425(第08期);第942-944页 * |
间日疟原虫和恶性疟原虫乳酸脱氢酶基因的序列和重组抗原表位分析;江莉等;《中国寄生虫学与寄生虫病杂志》;20100430(第02期);第103-105页 * |
间日疟原虫部分乳酸脱氢酶基因的克隆及序列分析;郝文波等;《热带医学杂志》;20060828(第08期);第873-876页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110951703A (zh) | 2020-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111349617B (zh) | 一种分泌抗Tau或pTau-181/231/396单克隆抗体杂交瘤细胞株及其应用 | |
CN108084255B (zh) | 一种重组犬c反应蛋白及其单克隆抗体的制备 | |
CN105542014B (zh) | Tp重组抗原及其制备方法和应用 | |
CN110845582B (zh) | 一种猫细小病毒重组蛋白及其单克隆抗体的制备 | |
CN110885370B (zh) | 分泌番茄环斑病毒单克隆抗体的杂交瘤细胞株及其抗体和抗体制备方法 | |
CN114133452B (zh) | 一种肝素结合蛋白抗体及其试剂盒、应用 | |
CN110951703B (zh) | 一种间日疟原虫乳酸脱氢酶重组蛋白及其单克隆抗体的制备 | |
CN112521497B (zh) | 肌红蛋白单克隆抗体的制备和应用 | |
CN113045666B (zh) | 胃蛋白酶原ii单克隆抗体及其应用 | |
CN112608385B (zh) | 一种犬脑钠肽(bnp)单克隆抗体的制备 | |
CN109142738A (zh) | Ecm1作为血清学检测肝纤维化的标志物及其应用 | |
CN110903359B (zh) | 一种空肠弯曲菌重组蛋白及其单克隆抗体的制备 | |
CN115286715B (zh) | 一种抗cd3的纳米抗体或其抗原结合部分及其制备方法 | |
CN110540966B (zh) | 人流感嗜血杆菌表面蛋白单克隆抗体及抗原捕获elisa试剂盒 | |
CN114195892A (zh) | 一种人胰岛素单链前体残留检测控制方法 | |
CN111978382B (zh) | 一种球形孢子丝菌Gp70重组蛋白的制备方法及其应用 | |
CN111909949B (zh) | 一种球形孢子丝菌hsp70_5重组蛋白的制备方法及其应用 | |
CN107586337B (zh) | 一种小鼠抗人kiaa0100蛋白单克隆抗体的制备方法 | |
CN112521461B (zh) | 甲型肝炎病毒重组蛋白的制备及其快速检测方法 | |
CN110054675B (zh) | 免疫原性多肽以及抗ttc36抗体cp4-3及应用 | |
CN109762058A (zh) | 一种重组g-17蛋白及其单克隆抗体的制备 | |
CN112480247B (zh) | 抗人血清白蛋白单克隆抗体 | |
CN110129277B (zh) | 一种肝癌诊断标志物brix1及其应用 | |
CN114805564B (zh) | 特异性识别SARS-CoV-2 S蛋白NTD区域的单克隆抗体及应用 | |
CN117024595B (zh) | 抗人st2的单克隆抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240326 Address after: Room 401, Building 26, Room 301, and Room 401, Building 27, No. 488-1 Donghu North Road, Donghu Street, Linping District, Hangzhou City, Zhejiang Province, 311100 Patentee after: Hangzhou Xinmai Biotechnology Co.,Ltd. Country or region after: China Address before: 311100 Room 401, building 16, No. 488-1, Donghu North Road, Donghu street, Yuhang District, Hangzhou City, Zhejiang Province Patentee before: HANGZHOU XIANZHI BIOTECHNOLOGY CO.,LTD. Country or region before: China |
|
TR01 | Transfer of patent right |